Hypoglycaemia is reduced with use of inhaled Technosphere^® Insulin relative to insulin aspart in type 1 diabetes mellitus.

ABSTRACT:

Aim

To evaluate the effect of final HbA_1c levels on the incidences of hypoglycaemia in participants with type 1 diabetes treated with inhaled Technosphere^® Insulin or subcutaneous insulin aspart, reported in alignment with the International Hypoglycaemia Study Group recommendations.

Methods

In the randomized, phase 3, multicentre AFFINITY-1 study, adults (N = 375) who had type 1 diabetes for ≥ 12 months and an HbA_1c level of 58-86 mmol/mol (7.5-10.0%) were randomized to receive basal insulin plus either inhaled Technosphere Insulin or subcutaneous insulin aspart. This was a post-hoc regression analysis on a subset (N = 279) of the randomized AFFINITY-1 cohort for whom baseline and end-of-treatment HbA_1c values were reported. Primar

SUBMITTER: Seaquist ER 

PROVIDER: S-EPMC7216876 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature